ATH 0.00% 0.5¢ alterity therapeutics limited

Antibiotic resistance market now 8 billions, page-8

  1. 2,757 Posts.
    lightbulb Created with Sketch. 958
    8 billion / year is a lot for a 60 M company but it may be not only 8 B because this estimate does not include the food industry which may be even a bigger antibiotic user than usage in humans. But we are not yet there, in spite of a deal with one of the big antibiotic manufacturers will be coming perhaps within weeks.

    Harbison-Price et al, 2020:
    Multiple Bactericidal Mechanisms of the Zinc Ionophore PBT2

    "We propose that this novel and multitarget mechanism of PBT2 makes the development of cross-resistance to medically important antimicrobials unlikely"
    "More antimicrobials are used in food-producing animals than in humans, and the extensive use of medically important human antimicrobials poses a significant public health threat in the face of rising antimicrobial resistance".
    "----we show that PBT2 has multiple mechanisms of antimicrobial action, making the development of PBT2 resistance unlikely".


    So most likely PBT2 will be used also in the food industry because it will most likely prevent the development of antibiotic resistance.
 
watchlist Created with Sketch. Add ATH (ASX) to my watchlist
(20min delay)
Last
0.5¢
Change
0.000(0.00%)
Mkt cap ! $26.22M
Open High Low Value Volume
0.6¢ 0.6¢ 0.5¢ $168.8K 33.11M

Buyers (Bids)

No. Vol. Price($)
44 41248698 0.5¢
 

Sellers (Offers)

Price($) Vol. No.
0.6¢ 19271266 14
View Market Depth
Last trade - 16.10pm 10/05/2024 (20 minute delay) ?
Last
0.5¢
  Change
0.000 ( 16.7 %)
Open High Low Volume
0.6¢ 0.6¢ 0.5¢ 10016772
Last updated 15.59pm 10/05/2024 ?
ATH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.